Evidence map›Paper›PMID 31774938›Full record

ArticleChemMedChem2020

Optimized Inhibitors of MDM2 via an Attempted Protein-Templated Reductive Amination.

Ramon van der Vlag, M Yagiz Unver, Tommaso Felicetti, Aleksandra Twarda-Clapa, Fatima Kassim, Cagdas Ermis, Constantinos G Neochoritis, Bogdan Musielak, Beata Labuzek, Alexander Dömling and 2 more

Open access · hybridAbstract read
In one paragraph

Article in ChemMedChem, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 5 countries.

Ramon van der VlagStratingh Institute for Chemistry, University of Groningen, Nijenborgh 7, 9747 AG, Groningen, The Netherlands.
M Yagiz UnverStratingh Institute for Chemistry, University of Groningen, Nijenborgh 7, 9747 AG, Groningen, The Netherlands.ORCID 0000-0002-9797-7832
Tommaso FelicettiStratingh Institute for Chemistry, University of Groningen, Nijenborgh 7, 9747 AG, Groningen, The Netherlands.ORCID 0000-0001-9369-8564
Aleksandra Twarda-ClapaFaculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Krakow, Poland.ORCID 0000-0003-2532-5672
Fatima KassimStratingh Institute for Chemistry, University of Groningen, Nijenborgh 7, 9747 AG, Groningen, The Netherlands.
Cagdas ErmisStratingh Institute for Chemistry, University of Groningen, Nijenborgh 7, 9747 AG, Groningen, The Netherlands.
Constantinos G NeochoritisDepartment of Pharmacy, Drug Design group, University of Groningen, A. Deusinglaan 1, Groningen, The Netherlands.ORCID 0000-0001-5098-5504
Bogdan MusielakFaculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Krakow, Poland.ORCID 0000-0002-1665-5920
Beata LabuzekFaculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Krakow, Poland.ORCID 0000-0001-5029-1473
Alexander DömlingDepartment of Pharmacy, Drug Design group, University of Groningen, A. Deusinglaan 1, Groningen, The Netherlands.ORCID 0000-0002-9923-8873
Tad A HolakFaculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387, Krakow, Poland.ORCID 0000-0001-9369-6024
Anna K H HirschStratingh Institute for Chemistry, University of Groningen, Nijenborgh 7, 9747 AG, Groningen, The Netherlands.ORCID 0000-0001-8734-4663
University of Groningen · NLJagiellonian University · PLUniversity of Crete · GR

Funding

Real-time discovery of inhibitors among billion compounds for preview and downloadR01GM097082 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CAMACHO, CARLOS J. · 2011 to 2020
$2.5M
NIGMS NIH HHS R01 GM097082
6 · The paper itself

Abstract

Innovative and efficient hit-identification techniques are required to accelerate drug discovery. Protein-templated fragment ligations represent a promising strategy in early drug discovery, enabling the target to assemble and select its binders from a pool of building blocks. Development of new protein-templated reactions to access a larger structural diversity and expansion of the variety of targets to demonstrate the scope of the technique are of prime interest for medicinal chemists. Herein, we present our attempts to use a protein-templated reductive amination to target protein-protein interactions (PPIs), a challenging class of drug targets. We address a flexible pocket, which is difficult to achieve by structure-based drug design. After careful analysis we did not find one of the possible products in the kinetic target-guided synthesis (KTGS) approach, however subsequent synthesis and biochemical evaluation of each library member demonstrated that all the obtained molecules inhibit MDM2. The most potent library member (K

Indexed as

AldehydesAminationDose-Response Relationship, DrugDrug DiscoveryEnzyme InhibitorsHumansMolecular Docking SimulationMolecular StructureProtein BindingProto-Oncogene Proteins c-mdm2Structure-Activity RelationshipAldehydesEnzyme InhibitorsMDM2 protein, humanProto-Oncogene Proteins c-mdm2

Identifiers

PMID31774938
PMCPMC7064911
OpenAlexW2991642291

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.